These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
445 related items for PubMed ID: 25756067
1. Delamanid for the treatment of pulmonary multidrug-resistant tuberculosis. Thakare R, Soni I, Dasgupta A, Chopra S. Drugs Today (Barc); 2015 Feb; 51(2):117-23. PubMed ID: 25756067 [Abstract] [Full Text] [Related]
2. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB). Liu Y, Matsumoto M, Ishida H, Ohguro K, Yoshitake M, Gupta R, Geiter L, Hafkin J. Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909 [Abstract] [Full Text] [Related]
3. Delamanid for multidrug-resistant pulmonary tuberculosis. Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, Gao M, Awad M, Park SK, Shim TS, Suh GY, Danilovits M, Ogata H, Kurve A, Chang J, Suzuki K, Tupasi T, Koh WJ, Seaworth B, Geiter LJ, Wells CD. N Engl J Med; 2012 Jun 07; 366(23):2151-60. PubMed ID: 22670901 [Abstract] [Full Text] [Related]
4. Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability. Kwon YS, Jeong BH, Koh WJ. Expert Opin Pharmacother; 2015 Feb 07; 16(2):253-61. PubMed ID: 25327169 [Abstract] [Full Text] [Related]
7. Profile of delamanid for the treatment of multidrug-resistant tuberculosis. Szumowski JD, Lynch JB. Drug Des Devel Ther; 2015 Feb 07; 9():677-82. PubMed ID: 25678771 [Abstract] [Full Text] [Related]
8. Current Status of Delamanid in the Management of MDR Tuberculosis. Karekar SR, Marathe PA. J Assoc Physicians India; 2018 Jul 07; 66(7):72-75. PubMed ID: 31325268 [Abstract] [Full Text] [Related]
9. Undergraduate Medical Teaching: Time to integrate? Ravikirti, Sharma S. J Assoc Physicians India; 2018 Aug 07; 66(8):85-86. PubMed ID: 31324092 [Abstract] [Full Text] [Related]
18. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany. Wirth D, Dass R, Hettle R. BMC Health Serv Res; 2017 Mar 08; 17(1):182. PubMed ID: 28270207 [Abstract] [Full Text] [Related]